Biomica

Company Overview

Snapshot

Founded in June 2017, Biomica operates with 11–50 employees. The company has raised $37 million across two funding rounds from three investors. In June 2026, Biomica's subsidiary, Evogene, announced the successful completion of a Phase 1 clinical study for BMC128, a rationally designed live bacterial product, in combination with nivolumab.

Business overview

Biomica is a clinical-stage biopharmaceutical company focused on developing innovative microbiome-based therapeutics. The company targets immune-mediated and infectious diseases, with a particular emphasis on Immuno-Oncology and GI-related disorders. Utilizing its proprietary PRISM (Predictive, high Resolution, Integrative Selection of Microbes) platform, Biomica identifies and targets key microbes, metabolites, and other microbiome-related components through both biological and small-molecule approaches. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In June 2026, Biomica's parent company, Evogene, announced the successful completion of a Phase 1 clinical study for BMC128, a microbiome-based therapeutic, in combination with nivolumab. This milestone is significant as it validates the potential of Biomica's rationally designed live bacterial products in immuno-oncology, indicating progress in bringing novel treatments to market for refractory RCC, NSCLC, and melanoma.

Company Intelligence Q&A

What was the outcome of the Phase 1 clinical study for BMC128?

In June 2026, Biomica's subsidiary, Evogene, announced the successful completion of a Phase 1 clinical study for BMC128, a rationally designed live bacterial product, in combination with nivolumab.

When did Biomica present positive clinical data from its Phase 1 trial for BMC128?

In May 2024, Biomica presented positive clinical data updates from the ongoing Phase 1 trial of its microbiome-based therapeutic, BMC128, for refractory RCC, NSCLC, and melanoma.

When did Biomica complete Phase I trial enrollment for its microbiome-based immuno-oncology drug?

In January 2024, Biomica successfully completed Phase I trial enrollment for its microbiome-based immuno-oncology drug.

What was the outcome of Biomica's financing round in April 2023?

In April 2023, Biomica closed a $20 million financing round, led by Shanghai Healthcare Capital.

What agreement did Biomica sign in October 2021?

In October 2021, Biomica and Rambam Health Care Campus signed an agreement for a clinical trial of Biomica's microbiome-based immuno-oncology drug.